BR0210976A - Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia - Google Patents

Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia

Info

Publication number
BR0210976A
BR0210976A BR0210976-0A BR0210976A BR0210976A BR 0210976 A BR0210976 A BR 0210976A BR 0210976 A BR0210976 A BR 0210976A BR 0210976 A BR0210976 A BR 0210976A
Authority
BR
Brazil
Prior art keywords
once daily
therapy
carvedilol
daily therapy
pharmaceutical composition
Prior art date
Application number
BR0210976-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Dilip Shantilal Shanghvi
R Bala Ramesha Chary
Z Ziauddin Tyebji
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR0210976A publication Critical patent/BR0210976A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Packaging Frangible Articles (AREA)
  • Indole Compounds (AREA)
BR0210976-0A 2001-05-17 2002-05-10 Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia BR0210976A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (enExample) 2001-05-17 2001-05-17
PCT/IN2002/000118 WO2002092078A1 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Publications (1)

Publication Number Publication Date
BR0210976A true BR0210976A (pt) 2004-10-05

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210976-0A BR0210976A (pt) 2001-05-17 2002-05-10 Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia

Country Status (16)

Country Link
US (1) US20030035836A1 (enExample)
EP (1) EP1395258A1 (enExample)
JP (1) JP2004534031A (enExample)
KR (1) KR20040037026A (enExample)
CN (1) CN1525855A (enExample)
AU (1) AU2002314515B2 (enExample)
BE (1) BE1014328A7 (enExample)
BR (1) BR0210976A (enExample)
CA (1) CA2447005A1 (enExample)
HU (1) HUP0400607A3 (enExample)
IN (1) IN191028B (enExample)
MX (1) MXPA03010501A (enExample)
PL (1) PL370589A1 (enExample)
RU (1) RU2003133446A (enExample)
WO (1) WO2002092078A1 (enExample)
ZA (1) ZA200309724B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3024399A (en) 1998-04-03 1999-10-25 Bm Research A/S Controlled release composition
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1929998A3 (en) * 2001-09-21 2008-11-26 Egalet A/S Controlled release solid dispersions of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
AU2003251627A1 (en) 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
US20060258652A1 (en) * 2002-11-22 2006-11-16 Haj-Yehia Abdullah I Beta-blockers having antioxidant and no-donor activity
EP1610768B1 (en) 2003-03-26 2008-07-02 Egalet A/S Matrix compositions for controlled delivery of drug substances
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
ATE445393T1 (de) * 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
ES2401769T5 (es) * 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
JP2007512372A (ja) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
SG174026A1 (en) 2006-08-03 2011-09-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
TW201200165A (en) * 2010-02-22 2012-01-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
RU2665372C2 (ru) 2012-09-03 2018-08-29 Дайити Санкио Компани, Лимитед Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
PL335619A1 (en) * 1997-03-11 2000-05-08 Darwin Discovery Ltd Dosage forms including separate parts containing r and s enantiomers
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
JP2003514019A (ja) * 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
WO2001074356A1 (en) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
HUP0400607A2 (hu) 2004-07-28
PL370589A1 (en) 2005-05-30
AU2002314515B2 (en) 2007-08-16
CA2447005A1 (en) 2002-11-21
IN191028B (enExample) 2003-09-13
ZA200309724B (en) 2005-05-25
KR20040037026A (ko) 2004-05-04
MXPA03010501A (es) 2004-03-02
RU2003133446A (ru) 2005-03-10
WO2002092078A1 (en) 2002-11-21
JP2004534031A (ja) 2004-11-11
BE1014328A7 (fr) 2003-08-05
CN1525855A (zh) 2004-09-01
US20030035836A1 (en) 2003-02-20
HUP0400607A3 (en) 2005-07-28
EP1395258A1 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
Brahmkshatriya et al. Clinical evaluation of Cissus quadrangularis as osteogenic agent in maxillofacial fracture: A pilot study
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
Morgan et al. Surgical management of macroglossia in children
HUP0400607A2 (hu) Orális szabályozott hatóanyag-leadású készítmény szív- és keringési betegségek napi egyszeri gyógyszerezéssel való kezelésére és megelőzésére
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
JP2001510795A5 (enExample)
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
Rizer et al. Macroglossia: etiologic considerations and management techniques
Hecker Maxillofacial rehabilitation of a large facial defect resulting from an arteriovenous malformation utilizing a two-piece prosthesis
Kapetanakos et al. Rehabilitation of a patient after a total maxillectomy with a 2-piece magnetically retained obturator: A clinical report
BR112019026029A2 (pt) Formulações farmacêuticas orais de remogliflozina
Kumar et al. Management of postburn perioral contracture using a customized static commissural splint and intralesional injections of triamcinolone
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
Deepika et al. Application of Polyvinyl chloride sheet as delayed surgical obturator in maxillectomy defects secondary to mucormycosis-A case series
US20030109495A1 (en) Nutraceutical solutions comprising dimethyl sulfoxide
BR9909786A (pt) Utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar formas brandas/ precoces de copd (doença pulmonarobstrutiva crÈnica
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
BR9916963A (pt) Bupropiona para tratamento de doenças virais
Pathak et al. Management of khalitya (hair fall) by ayurvedic formulations-a review
Savion et al. Construction of a surgical stent for posttraumatic nasal synechia
Hussain et al. The Evaluation of the Efficacy of Ketoprofen Analgesic Patches in Pain Control After Transalveolar Extraction of Impacted Third Molar

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.